The Black Hole

Both David and Jonathan hope that many new and good things can come from this period of lockdown.

BY DAVID KENT | JUN 23 2020

This quarter has been different there is no doubt about that. Both Jonathan and I have spent lockdown with working partners (medical doctor and scientist) and two little ones each (all four kiddies under the age of five) and we were chatting the other day about how odd it is that he and I have only ever met physically in person three times. Sometimes people just get on and have aligned goals and ambitions, and The Black Hole has been a tremendous pleasure to share with Jonathan (and Beth Snow before!). This period of enforced online interaction has led to some serious Zoom fatigue, but we both hope that many new and good things can come from this period of lockdown as youll see from the range of posts below.

This quarters most popular posts were my recent post on career considerations during lockdown and Joanthans post from last summer entitled You are not a failure for wanting to leave academia which we imagine also got some extra readers during lockdown for similar reasons as the career considerations post. We hope that readers enjoy these and others. We also hope to write more on the positive things that might emerge from the introspective journey that many of us have been on over the last months (or the one well go on after life gains some semblance of normality!). Our recent posts are listed below:

This quarter Dave has also written some more science-y stuff with a series of articles exploring recent scientific advances in blood stem cell gene therapy for a wide range of diseases over on the Signals blog:

Were looking forward to getting back to normal (even to whatever the new normal will be) and as always, encourage our readers to contribute their own articles to this column to gain some exposure for issues near and dear to their hearts.

Original post:
Quarterly summary: the COVID-19 lockdown and the importance of scientists - University Affairs

Recommendation and review posted by Bethany Smith

MARQUETTE COUNTY, Mich. (WLUC) - Beginning Monday, July 13, the KMQT WSR-88D Radar operated by NOAAs National Weather Service near Marquette, will be down for approximately two weeks for an important upgrade.

Technicians will refurbish and replace the pedestal, one of the most critical components of the radar, which is necessary for antenna rotation and positioning to capture data in all directions. The components are extremely heavy and will require the radome to be removed by crane and replaced when the work is completed.

The radar and pedestal were designed to last 25 years, and this radar has exceeded its life-span. This activity is necessary to keep the radar functioning for another 20 years or more.

The pedestal refurbishment is the third major project of the NEXRAD Service Life Extension Program, a series of upgrades that will keep our nations radars viable into the 2030s. NOAAs National Weather Service, the United States Air Force, and the Federal Aviation Administration are investing $135 million in the eight year program. The first project was the installation of the new signal processor and the second project was the refurbishment of the transmitter. The fourth project will be the refurbishment of the equipment shelters. The Service Life Extension Program will be complete in 2023.

During the downtime, adjacent radars will be available, including: Green Bay (KGRB), Duluth (KDLH), and Gaylord (KAPX). For direct access to any of these surrounding radar sites, visit https://radar.weather.gov/

The KMQT WSR-88D is part of a network of 159 operational radars. The Radar Operations Center in Norman, Oklahoma, provides lifecycle management and support for all WSR-88Ds.

The National Weather Service near Marquette, Michigan can be found on the web at weather.gov/mqt or on social media, NWSMarquette on Facebook or NWSMarquette on Twitter.

Go here to read the rest:
National Weather Service announces radar outage during major upgrade in July - UpperMichigansSource.com

Recommendation and review posted by Bethany Smith

There is incredible power in our daily habits. This can be a positive thingincorporating healthy habits can have a tremendous impact on our wellbeing and help us feel more focused and productive as we go about our workdayor a negativein the case of unhealthy habits that undermine our health and make it harder to function optimally.

Sometimes the bad habits or the parts of our routine that arent helping us are obvious, but other times, we need to dig deeper to understandbut how? There is a lot of information out there, but it can be hard to know what to apply to your own situation. I cant tell you how many times I have seen someone try a diet or workout routine or product that just wasnt a good fit for them, only to wind up feeling more confused about their own healthand not any better.

The foods that some people thrive on may not be a good fit for othersand health experts say that's ... [+] okay.

I interviewed several leading health and wellness experts about the importance of taking an individualized approach to wellness, practicing bio-individuality by honoring their unique needs.

Dr. Will Cole, IFMCP, DC, leading functional medicine expert and author of The Inflammation Spectrum and Ketotarian, explains, We each have our own biochemistry - a unique combination of genetics that is different than anyone else. Because of this, what affects us health wise (diet, environmental triggers) and how that plays out in your health case (symptoms, diagnoses) is going to be different from person to person. Ultimately, there is no one-size-fits-all when it comes to health.

He adds, While there are certain foods that can trigger inflammation in most people such as conventional sugar and processed foods, there are also so-called healthy foods that can trigger inflammation in one person but not another. For example, I've seen spinach be an inflammatory trigger for some peopleand most people would agree that spinach is a 'healthy' food. But for some individuals those healthy foods aren't so healthy. Dr. Cole, who guides patients through specialized elimination diets explains that going through an individualized elimination diet will help you discover your individual food triggers so you can build the healthiest diet for you.

Dietitian Maya Feller counsels patients with a wide variety of needs and tailors her recommendations to what that individual person may need. When we look at population-wide data, we know many Americans are not meeting the recommended intake for fiber, choline, magnesium, iron, calcium, vitamins A, D, E and potassium. However, each person may have specific concerns depending on their health history, diet pattern, medications, lifestyle and work schedule, just to name a few factors.

Feller, who is a partner of Life Extension, is a firm believer in working with a credentialed healthcare provider and using lab tests to assess what your individual needs are in regard to which gaps in the diet you need to fill. When someone is unable to meet their needs through food, she says, I think safe supplementation is key.

Practicing bio-individuality involves tuning in to the foods and lifestyle habits that support your ... [+] health and wellbeing.

Another area where paying attention to your unique needs is your skincare. Whether we are interacting with people in person or virtually, feeling confident in our skins health and appearance can play a role in how we present ourselves in our work life.

Dr. Kiran Mian is an aesthetic and medical dermatologist in New York City. She says, There are many factors that play into what our skin looks and feels like, including our diet, our sleeping habits, our mood and stress level, as well as our genetics. Our genetics even determine how our bodies handle these different factors. Speaking to a board certified dermatologist can help tease out the different factors affecting your skin. For example, I had a patient continuously breaking out on the left side of his face, and it turns out thats where his headset sat while he was at work. I also suggest my patients keep a food and skincare journal. Writing down what you ate, how much youve slept, and how your skin has been going during that time helps us find patterns. Its not always a direct causation, but an overall pattern were looking for.

Because social media is where so many people go for health information and inspiration, its important to consider how what we see may impact how empowered we feel to practice bio-individuality as opposed to trying to conform to standards and ideals that may not apply to us at all.

When we think about the wellness space historically, says Feller, it's been exclusive and has used white people as the barometer, asking people, regardless of where they are to blind themselves up with a white ideal. If were able to expand that space, that will make it possible for people with more diverse backgrounds from more places to be a part of that conversation...all of those people can be in the space in a way where they are seen and heard without asking them to shift to a white ideal.

Dr. Cole echoes, Health and wellness can do a better job at representing other people and giving them a chance to share their stories and showcase their wellness journey. Whether that is someone wanting to be healthy or get into the wellness field as a practitioner, the more the wellness community can practice diversity, the more we can empower everyone to take back control of their health.

Racial diversity is important so that people feel represented, seen, heard, and part of the conversation, says Dr. Mian. We are all human, and human skin under the microscope looks the same. However, all the factors that influence skin are different, based on our cultures. This is a beautiful thing that should be celebrated.

Here is the original post:
Wellness Experts Discuss The Importance Of Individualizing Your Approach To Health - Forbes

Recommendation and review posted by Bethany Smith

By Kelli McGrane, MS, RD

Zinc is an essential micronutrient that's needed for numerous functions in your body. It's also important for a strong immune system and helps keep your skin, eyes, and heart healthy.

While there are many food sources of zinc, including meat and shellfish, some people may be at a higher risk of not getting enough zinc in their diets.

For example, those with inadequate access to food, pregnant or breastfeeding women, vegetarians and vegans, people with gastrointestinal disorders, and individuals taking certain medications like diuretics and anticonvulsants may benefit from a zinc supplement.

The zinc supplements in this review are all manufactured by reputable companies that follow Good Manufacturing Processes (GMP), use high quality ingredients, and test for purity and quality.

Here are the 10 best zinc supplements to help you meet your nutritional needs.

General price ranges with dollar signs ($ to $$) are indicated below. One dollar sign means the product is rather affordable, whereas three dollar signs indicate a higher price range.

Generally, prices range from $0.08$1.39 per serving, or $5.99$38.90 per container, though this may vary depending on where you shop.

Pricing guide

Note that the serving sizes vary. Some supplements require two capsules per serving, while the serving size for others may be 1 teaspoon (5 mL), 1 mL, or one capsule, tablet, or lozenge.

Price: $

Thorne Research is a supplement company that has its own dedicated scientists, labs, and research facilities for nutrition supplements.

All of their products are made in a lab that meets regulations and standards set by NSF International and the Therapeutic Goods Administration (TGA), which is a regulatory body in Australia that's responsible for assessing the safety of supplements.

Furthermore, their products are NSF Certified for Sport. This means that the products are tested to ensure the absence of more than 200 substances banned by many major athletic organizations.

Thorne Research's Zinc Picolinate is one of the best zinc supplements on the market due to the company's high quality standards, purity of ingredients, and form of zinc used.

Older research suggests that zinc picolinate may be one of the easiest forms of zinc for your body to digest and absorb.

One tablet of this supplement provides 30 mg of zinc picolinate. For best results take one tablet per day, or as recommended by your healthcare provider.

Shop for Thorne Research's Zinc Picolinate online.

Price: $

Chelated zinc is a type of zinc supplement that uses a chelating agent to help your body absorb zinc more easily.

While there are several chelated zinc supplements on the market, one of the best options is NOW Foods' Zinc Glycinate softgels.

Each softgel contains 30 mg of zinc glycinate a form of zinc that human and animal studies suggest may be better absorbed than other types of zinc.

All NOW Foods supplements are certified by Underwriters Laboratories and follow GMP to ensure the quality and accuracy of their products. Additionally, these supplements tend to be more affordable than many other high quality brands.

Shop for NOW Foods Zinc Glycinate Softgels online.

Nature's Way produces high quality supplements that are more affordable than many other brands on the market.

All of their supplements are manufactured in facilities that NSF has certified as meeting GMP requirements, which include a set of guidelines to ensure accuracy, quality, and purity of products.

In addition, their products are non-GMO, organic, and TRU-ID certified. TRU-ID certification is a relatively new independent testing program that uses DNA to verify the authenticity of ingredients in supplements.

For zinc products, Nature's Way offers zinc chelate capsules and zinc lozenges, both of which are budget-friendly.

Price: $

These zinc chelate capsules are gluten-free and provide 30 mg per capsule.

For best results, adults and adolescents over the age of 14 should take one capsule daily with food, or as recommended by your healthcare provider.

Shop for Nature's Way Zinc Chelate Tablets online.

Price: $

For those interested in lozenges, each of Nature's Way's Zinc Lozenges provides 23 mg of zinc, as well as 100 mg of vitamin C and 20 mg of Echinacea purpurea.

Although the label suggests that adults can take up to 6 lozenges per day, this would push your daily zinc intake way over the suggested 40-mg tolerable upper intake level (UL) set for zinc.

Taking too much zinc can have adverse effects on your health and may interfere with the absorption of other nutrients. It's important that you check with your healthcare provider before taking high dose zinc supplements to ensure safety.

Shop for Nature's Way Zinc Lozenges online.

Price: $

While it's not always obvious, some supplements can contain animal-derived ingredients, making the product unsuitable for vegans.

Some commonly used ingredients that aren't vegan-friendly include digestive enzymes like lipase, caprylic acid from milk, gelatin, and magnesium stearate, which is often pork-derived.

Garden of Life is a whole-foods-based supplement brand with products that are certified organic and non-GMO verified.

Their Vitamin Code Raw Zinc is a good option for vegans, as it's third-party tested to ensure the product is vegan, as well as gluten-free.

In addition to providing 30 mg of plant-based zinc, each serving also contains vitamin C, a raw organic fruit and vegetable blend, and live probiotics and enzymes to support healthy digestion.

It's recommended that adults take one serving of 2 capsules per day with or without meals. For those who have difficulty swallowing pills, the capsules can also be opened to pour the contents into a glass of water or other beverage.

Shop for Garden of Life Vitamin Code Raw Zinc online.

For those who have difficulty swallowing pills, liquid forms of zinc may be better tolerated.

Price: $$

Metagenics is a supplement company devoted to transparency and quality. Each ingredient and supplement batch is tested for quality, and you can even access a detailed testing report for the specific supplement you're looking to buy.

As part of their quality assurance, all Metagenics supplements are USP-verified and meet NSF and Therapeutic Goods Administration (TGA) safety and quality regulations.

Their Zinc Drink liquid supplement contains only water and 15 mg of zinc sulfate per serving, making it free of any additives and preservatives.

For best results, take 1 teaspoon (5 mL) per day of the Zinc Drink between meals. While you can take the supplement on its own, it can also be mixed into a glass of water.

Shop for Metagenics Zinc Drink online.

Price: $$

Peak Performance supplements are made in the United States and developed for busy athletes and professionals.

In addition to being free of major allergens, including soy, dairy, wheat, egg, shellfish, and peanuts, Peak Performance's Raw Ionic Liquid Zinc is also vegan-friendly.

By running zinc through a high pressure, low heat process, the zinc particles in this liquid supplement are very small in size, which may make it easier for your body to absorb.

One full dropper provides 15 mg of zinc sulfate a form of zinc that has been shown to help prevent zinc deficiency, reduce symptoms of severe acne, and possibly help slow the progression of age-related macular degeneration (AMD) (6Trusted Source, 12Trusted Source).

All Peak Performance supplements undergo third-party testing for quality and accuracy. They're also manufactured following Food and Drug Administration (FDA), GMP, and NSF regulations and standards.

Adults should take one full dropper (1 mL) once a day on an empty stomach, or use as directed by your healthcare provider.

Shop for Peak Performance Raw Ionic Liquid Zinc online.

Price: $

Zinc lozenges are small tablets that are meant to dissolve slowly in your mouth. They're typically taken for short periods to help reduce the symptoms and duration of the common cold.

In fact, one review found that consuming a dose of 8092 mg of zinc from zinc lozenges per day helped reduce the duration of the common cold by up to 33%.

Life Extension has been making high quality supplements for over 40 years.

In addition to being manufactured in an NSF-registered GMP facility, each product has a certificate of analysis that's available for consumers to confirm the quality and accuracy of a specific product.

Life Extension's Enhanced Zinc Lozenges contain 18.75 mg of zinc acetate a form of zinc that has been shown to shorten the duration of colds by up to 40%.

Adults can take 1 lozenge every 2 hours up to 8 times a day. However, it's not recommended to consume these lozenges for more than 3 days in a row. Also, note that taking this supplement 8 times per day will greatly exceed the daily UL of 40 mg.

Shop for Life Extension Enhanced Zinc Lozenges online.

Price: $

If you're looking for an organic zinc supplement, NutriGold's Zinc Gold is one of the best options out there.

Each capsule contains 15 mg of whole-foods-based zinc that's derived from an organic sprouted blend, which the supplement claims may be gentler on your stomach.

Additionally, NutritGold's supplements are certified organic by SCS Global Services, an official partner of the United States Department of Agriculture (USDA) that sets sustainability, quality, and organic standards.

Each product is also third-party tested, as well as non-GMO and vegan certified.

Adults should take 1 capsule daily, or as directed by your healthcare provider.

Shop for NutriGold Zinc Gold online.

Price: $

If you're looking for a gluten-free zinc supplement, Pure Encapsulations is one of your best options.

The products are not only made in a facility that's NSF-registered GMP but also certified gluten-free by the Gluten-Free Certification Organization (GFCO). Plus, they contain zinc picolinate to optimize digestion and absorption.

For optimal results, it's recommended to take one 30-mg zinc picolinate capsule daily with food.

Shop for Pure Encapsulations Zinc online.

When choosing a zinc supplement, it's important to consider the type of zinc, dosage, and supplement form.

There are several types of zinc supplements. Some, such as zinc picolinate, may be better absorbed, while zinc acetate may be more effective at shortening the duration of the common cold.

As for dosage, the recommended daily dosage for adults is typically 1530 mg of elemental zinc per day. Elemental zinc is generally the amount listed on the label of your supplement.

Due to potential side effects of excess zinc, it's best not to exceed 40 mg per day unless under medical supervision.

Taking too much zinc can cause adverse side effects, such as decreased immune function, low copper levels, and reduced HDL (good) cholesterol levels.

Regarding the form, zinc supplements are available as capsules, lozenges, and liquids. For those who are unable or prefer not to swallow pills, liquid forms are likely a better option.

Before buying any supplement, it's important to research high quality, trustworthy brands to ensure both safety and accuracy.

Look for supplements that are produced by reputable manufactures and free of large amounts of added ingredients like fillers, additives, and preservatives.

A good way to ensure the quality of a product is to look for ones that have been certified by a third-party company, such as NSF International or Underwriters Labs.

Zinc is an essential nutrient that you need to get enough of in your diet. However, as not everyone is able to meet their need through foods alone, supplements can help reduce the risk of a zinc deficiency.

Of course, not all supplements are created equal. It's important to look for high quality products that have been tested to ensure quality and accuracy.

If you're concerned about your zinc intake, it's worth speaking with your healthcare provider to see if a zinc supplement is a good option, as well as to determine an optimal dose.

Reposted with permission from Healthline. For detailed source information, please view the original article on Healthline.

From Your Site Articles

Related Articles Around the Web

Go here to see the original:
The 10 Best Zinc Supplements of 2020 - EcoWatch

Recommendation and review posted by Bethany Smith

F-35A AF-6 releases inert B61-12 during a dual capable aircraft (DCA) test flight in the skies above Edwards Air Force Base, California, on Nov. 25, 2011. (All images: DoD)

It is not a secret that the F-35A, the CTOL (Convetional Take Off and Landing) variant of the Lightning II aircraft, will be dual capable aircraft (DCA), meaning that it will have the ability to deliver nuclear ordnance as well as conventional weapons. Such dual capability is expected to be included in the Block 4 software release, with initial capability for the B61-12 weapon. Although the F-35A DCA is scheduled to achieve nuclear certification in January, 2023, testing at the 461st FLTS, the test squadron that oversees developmental testing of all variants of the fifth-generation F-35 Lightning II at Edwards Air Force Base, California, has started in 2019.

Images just released by the F-35 Joint Program Office (the Department of Defenses agency responsible for developing and acquiring the F-35A/B/C) show various drop tests of inert nuclear bombs between 2019 and 2020.

The photos distributed to the DVIDS distribution service provide additional details about the dates when the tests were carried out: the first separation test with AF-1 flown by Jason Shulze was conducted on Jun. 27, 2019; sixth separation test with AF-1 (pilot unspecified) was carried out on Nov. 7, 2019; first separation test from AF-6 flown by Major Chris Beast Taylor was conducted on Nov. 25, 2019. Separation test #6 with AF-1 was carried out with F-35 AF-01 flown by Major Rachael Banshee Winiecki on Feb. 6, 2020. A more recent test with AF-6 was carried out on Apr. 2, 2020 (no additional detail can be gathered about this test).

As already explained in a previous article:

the B61-12 represent the latest LEP (Life-Extention Program) upgrade to the B61 line of nuclear weapons that has already been extensively tested with the F-15E Strike Eagles of the 422nd Test and Evaluation Squadron, back in 2015.

The Life Extension Program or LEP, will replace the B61 -3, -4, -7, and -10 mods, with the -12 that, along with the B83, will become the only remaining gravity delivered nukes in the inventory.

The B61-12 gravity bomb ensures the current capability for the air-delivered leg of the U.S. strategic nuclear triad well into the future for both bombers and dual-capable aircraft supporting NATO, said Paul Waugh, AFNWCs Air-Delivered Capabilities director in a U.S. Air Force release dated Apr. 13 (more or less when the world learned about the first use of the famous MOAB in Afghanistan). The B61-12 will be compatible with the B-2A, B-21, F-15E, F-16C/D, F-16 MLU, F-35 and PA-200 aircraft.

The LEP increases the B61s accuracy so much that it will have the same capability against hardened targets as the much more powerful weapons it is replacing.

With the integration of the B61-12, the iconic nuclear fighter role, performed in the past by the F-15E and F-16, is being passed to the F-35A to play a future role in national security. Other partner nations are slated to transfer the NATO nuclear role to the F-35A in the future.

Go here to see the original:
Here Are The First Photos Of The F-35A Jets Dropping Inert B61-12 Nuclear Bombs During DCA Tests - The Aviationist

Recommendation and review posted by Bethany Smith

A RNoAF towing a little sledge on an apron in Norway. (Image: screenshot from the video below).

The footage below shows an F-5A Freedom Fighter of the 336 Sqn of the RNoAF (Royal Norwegian Air Force) towing a person on a sort-of sledge on a frozen apron. According to the user who uploaded the clip to Youtube, when the technical status of our F-5B twoseaters went low, creative training methods were required. A funny scene from a 336 sqn video showing a F-5 fighter jet towing an instructor giving taxi instructions from a sledge.

Obviously, the description is hilarious: it looks like the personnel of the 336 Sqn based at Rygge, 60 kilometers outside Oslo, in eastern Norway, wanted to exploit the frozen surface of the apron for a joke and hooked a cable and an improvised sledge to the rear end of the F-5 for some fast turns during the taxi operations of the Tiger. At a certain point, the little sled capsizes and the military, holding the cable tight with his hands, is towed with his belly on the ground.

Although the engines were running at idle power for the taxi, at that distance, the person on the sledge, while risking to be crashed on the nearby hangar or against one of the fire extinguishers on the apron, was probably getting some of the exhaust gas and heat

The video is quite old (from an era when such jokes were much more frequent than nowadays, when some stunts would probably be punished), dating back to a period between 1987 and 2000 when the 336 Skvadron was disbanded (on Jun. 30, 2000).

The RNoAF started receiving the first Northrop F-5s in February 1966, when 9 Northrop F-5A(G) and 2 Northrop F-5B(G) arrived from Edwards AFB to Sola AB via Kirtland, Langley-Loring, Goose Bay, Sondrestfjorden, Keflavik, Prestwick. According to the Northrop F-5 Enthusiast Page, deliveries were completed by December 1970 and included 78 Northrop F-5(G), 23 of those funded through the US Military Aid Program; 16 RF-5A(G); 14 F-5B(G), 8 funded through MAP. The aircraft were upgraded beginning in 1984, through a Service Life Extension Programme (SLEP) started in 1984 and ended in 1986 that involved 17 Northrop F-5A and 13 F-5B(G) aircraft. A further upgrade included the ALE-38 chaff/flare dispenses (these were later replaced by ALE-40). As part of this upgrade, that was completed in November 1987, the aircraft received also light gray colours. Considered that the aircraft in the video show both the chaff and flares dispensers as well as the light grey color scheme, the clip must have been filmed after 1987.

H/T Alex Snow for posting the video

Read more from the original source:
Crazy Video Shows F-5A Freedom Fighter Towing A Person On A Little Sledge On A Frozen Apron in Norway - The Aviationist

Recommendation and review posted by Bethany Smith

Oscar Isaac casts doubts on whether or not hed return to the galaxy far, far away. David Koepp teases his still-alive Bride of Frankenstein remake. Warner Bros. is bringing The Halloween Tree to the big screen. Plus, get a look at Studio Ghiblis new CG movie, and Doom Patrol battles the terrifyingly disco Doctor Tyme. Spoilers now!

Deadline reports Warner Bros. is now developing a live-action film adaptation of Ray Bradburys The Halloween Tree with Will Dunn attached to write the screenplay. The original story concerns a group of trick-or-treaters who must rescue their friend, Pip, from The Land of the Dead with help from a mysterious man named Carapace Clavicle Moundshroud.

Appearing as a guest on The Boo! Crew podcast, David Koepp revealed his Bride of Frankenstein remake will deal with themes of life extension and bodily autonomy.

I just gave Universal a new draft about a month ago and they seem to really like it and theyre talking to directors. Its become the story of how are we extending our lives; can we create life, can we cheat death? It only gets more and more relevant over time. The big life extension work right now thats being out in Silicon Valley is overwhelming, impressive and scary, and I feel like a present day version of that is begging to be made.

The other thing is she is a woman who is not created but resurrected, and certain people feel ownership over her, and that almost too relevant today in the era of #metoo. What are her rights as a person, the person that exists, if you were dead? There are a lot of really interesting questions that are raised. Again, its horror effortlessly lending itself to metaphor.

[Bloody-Disgusting]

In a recent Deadline panel with Paul Schrader, Oscar Isaac stated hed only return to the Star Wars franchise if he needed a new house or something.

If I need another house or something. Its not really what I set out to do. What I set out to do was to make handmade movies, and to work with people that inspire me. Paul [Schrader]s movies, the things that hes made, its in my DNA. Im not alone, obviously. [For] every actor of a certain generation, those are the films that made them who they are, so thats certainly my case. It feels like for me a personal turning point and that, as far as Im concerned, it has nothing to do with the finished product. Its the process of doing this.

/Film has new images from Studio Ghiblis first-ever fully-CG animated feature, Aya and the Witch. Head over there to see the rest.

Reality takes a holiday in the trailer for Parallax (not to be confused with the DC Comics villain), opening July 10 in select global theatres.

In a recent interview with Deadline, the Duffer Brothers teased a couple of cool celebrity guest stars in the next season.

We have a couple of cool ones this year. Its a really fun way to meet one of your icons. You know, write a part for them and see if they want to do it.

[Deadline]

Nickelodeon has ordered a CG reboot of The Smurfs from Alvin and the Chipmunks writers Peter Saisselin and Amy Serafin with William Renaud (Caspers Scare School)attached to direct. [TV Line]

Speaking with Comic Book, Geoff Johns shared his thoughts on the yin and yang between Hourman and Doctor Mid-Nite.

If youre going to have Courtney actively recruiting like Hourman and Doctor Mid-Nite kind of always felt like a yin and yang to me because you have one thats very physical and one thats very intellectual. And I always saw them as The Flash and Green Lantern of the JSA and even when Rick and Beth joined Infinity Inc., they did it in the same issue. They just felt, theyve always felt like they were this interesting pair that, to me, that they look cool together, they were very different, they approach things differently.

Rex was an extrovert and Charles McNider was an introvert. They had these great dynamics between these two and I love the characters for that. And I felt like when we were introducing them both, if Courtney was actively pursuing Rick, well, then wed have Beth, as shes trying to recruit one person, while somebody else is kind of recruiting herself, is getting involved herself.

The 100 gets a backdoor pilot for a prequel series with the synopsis for Anaconda airing July 9.

THE PAST Clarke (Eliza Taylor) confronts a new adversary. A surprising connection takes us back to the past and the nuclear apocalypse that destroyed the Earth. Bob Morley, Marie Avgeropoulos, Lindsey Morgan, Richard Harmon, Tasya Teles, Shannon Kook, JR Bourne, Shelby Flannery and Chuku Modu also star. Ed Fraiman directed the episode written by Jason Rothenberg (#713).

[Spoiler TV]

KSiteTV has photos from the first two episodes of Doom Patrols second season, Fun Size Patrol and Tyme Patrol. Click on the relevant episode title for more.

The latest promo for the second season of The Twilight Zone includes brief glimpses of new footage.

Finally, a promo for this weeks season finale of Harley Quinn provides no new footage, instead, encouraging fans to catch up on DC Universe.

Banner art by Jim Cooke.

Read this article:
Updates from Stranger Things, Twilight Zone, and More - Gizmodo Australia

Recommendation and review posted by Bethany Smith

Dive Brief:

Known for its muscular dystrophy drugs Exondys 51 and Vydonys 53, Sarepta has quickly become a leader in gene therapy as well.

The last couple of years have seen the Cambridge, Massachusetts-based biotech ink gene therapy manufacturing and development deals, including a partnership with Roche that could be worth more than $3 billion.

Sarepta now has six gene therapies in clinical testing and another half dozen in preclinical stages. Most recently, the company announced positive, albeit early, results from a study of its experimental treatment for limb-girdle muscular dystrophy, a potentially deadly genetic disease.

With gene therapy set to become a cornerstone of its business, Sarepta is trying to avoid some the challenges presented by current technologies.

For example, when the company teamed up with North Carolina-based StrideBio late last year, one of the main goals was to use the partner's technology to "address re-dosing challenges in patients who have received AAV-delivered gene therapy." The deal came just days after a study testing an experimental gene therapy from Solid Biosciences, one of Sarepta's rivals, was paused due to a patient experiencing an immune response and organ complications.

"If successful, the ability to re-dose will be an enormous leap forward in the science of gene therapy and provide invaluable benefits to patients beyond those we anticipate with one-time dosing," said Doug Ingram, Sarepta's CEO, in a June 18 statement announcing the Selecta deal.

Under terms of that deal, Sarepta will pay Selecta an initial, undisclosed amount. Selecta is eligible to receive pre-clinical milestone payments, and could take home additional development, regulatory and commercial milestones should Sarepta exercise its options to enter a licensing agreement.

Specifically, the deal with Selecta centers on gene therapies for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies.

With Codiac, Sarepta has offered up $72.5 million in upfront and near-term license payments plus research funding. In addition, Codiak is eligible for "significant" milestone payments, according to Sarepta.

The two-year deal gives Sarepta the option to license Codiak's technology for up to five neuromuscular targets. The companies said they will collaborate on the design of exosomes that can deliver and release gene therapy, gene editing or RNA payloads. If Sarepta exercises an option, Codiak will then be in charge of research until right before the candidate goes into in-human testing. Sarepta is responsible for clinical development and commercial activities.

View original post here:
Sarepta tries to fine-tune its gene therapy approach - BioPharma Dive

Recommendation and review posted by Bethany Smith

Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.

Researchers have created a gene therapy approach that they say can convert any lab mouse into one that can be infected with SARS-CoV-2 and develop COVID-like lung disease. The team have made their gene therapy vector freely available to any researchers who wish to use it. The study was conducted by scientists at the University of Iowa (UI) Carver College of Medicine, US, and Medical University, Guangzhou, China.

There is a pressing need to understand this disease and to develop preventions and treatments, said Dr Paul McCray, UI professor of paediatrics and microbiology and immunology. We wanted to make it as easy as possible for other researchers to have access to this technology, which allows any lab to be able to immediately start working in this area by using this trick.

According to the researchers, the trick is the use of an adenovirus gene therapy vector that is inhaled by the mice to deliver the human angiotensin-converting enzyme 2 (ACE2) protein into mouse airway cells. This is the protein that SARS-CoV-2 uses to infect cells.Once the mouse airway cells express the hACE2 protein, the mice become susceptible to infection with the virus and they develop COVID-19-like lung symptoms.

Due to differences between the human and mouse ACE2 protein, wild-type mice are not susceptible to the SARS-Cov-2 virus, highlighting the need to develop models. Although the disease is not fatal in the models, the animals do get sick, losing weight and developing lung damage.

The vector is readily adaptable to any strain of mice (and other lab animals), which means research teams can rapidly convert mice with specific genetic traits into animals that are susceptible to SARS-Cov-2, allowing them to test whether those traits influence the disease.

The researchers showed that mice treated with this gene therapy could be used to evaluate a vaccine and several potential COVID-19 therapies, including a preventative strategy known as poly I:C, which boosts the innate immune response, convalescent plasma from recovered COVID-19 patients and the antiviral drug remdesivir. In each case, the therapies prevented weight loss, reduced lung disease and increased the speed of virus clearance in the mice. The team also showed that the mice are useful for studying important immune responses involved in clearing the SARS-CoV-2 virus.

The team say that their gene therapy vector is essentially an off-the-shelf tool that allows labs to create their own COVID-19 mouse model within a few days.

You can create these mice very quickly. You do not have to breed the strain, which is very time consuming and expensive, McCray explained. We think this technology will be useful for investigating COVID-19 lung disease and rapidly testing interventions that people think are promising for treating or preventing COVID-19.

The results were published in Cell.

Here is the original post:
Method to convert mice into COVID-19 models available to researchers - Drug Target Review

Recommendation and review posted by Bethany Smith

Emergent Biosolutions has set out to capture a share of the expanding viral vector and gene therapy sector.

The US countermeasures developer said it will spend $75 million to add viral vector and gene therapy manufacturing capacity at a facility in Canton, Massachusetts.

At present the plant which was acquired from Sanofi in 2017 produces drug substance for live viral vaccines, including Emergents smallpox jab ACAM2000.

Image: iStock/marchmeena29

Emergent said the investment will establish a multi-suite production operation with 1,000 L of manufacturing capacity.

Syed T. Husain, SVP & head of CDMO Business Unit at Emergent BioSolutions, told us there are significant opportunities in the gene therapy sector.

There is an unmet need in this area. We are seeing long wait times for customers in this space. Emergent has foundational expertise in live viral development and manufacturing, among other competencies, and we are building upon this capability to help produce these therapies and get them to patients.

He added, We are in discussions with interested customers, we would be able to initiate development services in 2022, paving the way for manufacturing in 2023 as the new facility comes online.

The plan is that the Canton facility will make drug substance for viral vector gene therapies, working alongside Emergents development services site in Gaithersburg and its manufacturing plant in Rockville, Maryland.

Emergent spoke about the expansion of its CDMO business during its Q1 conference call in May, predicting that the division would make a greater revenue contribution than forecast.

CFO Rick Lindahl told analysts We now expect a greater revenue contribution from CDMO than previously thought we currently see 2020 CDMO full-year revenue in a range of $125 million to $145 million, representing 55% to 80% growth as compared to 2019.

He added We continue to make progress on our strategic and financial objectives, including the expansion of the CDMO services businesses and its contribution to the overall business.

The gene therapy sector is expected to grow significantly over the next few years.

According to Allied Market Research the gene therapy market, which was valued at $393 million in 2018, is estimated to reach $6.2 billion by 2026, a CAGR of 34.8%.

This take is shared by analysts at Capstoneheadwaters who wrote that pharma interest in gene therapies will increase demand for CDMOs with production capacity.

The authors said, The increasing volume of gene therapy drugs under development will require greater manufacturing capacity and, in turn, greater utilization of CDMO capacity.

CDMOs may be able to increase penetration of their outsourced manufacturing services by providing services at the commercial stage in addition to the earlier stages of preclinical development and clinical trials.

They added, We see the injection of new capital into both gene therapy drug developers and CDMOs focused on gene therapy manufacturing as a positive industry dynamic.

Excerpt from:
Emergent to add gene therapy capacity - Bioprocess Insider - BioProcess Insider

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today presented data from preclinical studies of its hemophilia B gene therapy CB 2679d-GT at the WorldFederation of Hemophilia Virtual Summit, taking place from June 14 -19, 2020.

The oral presentation, entitled: Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy, given by Dr. Grant Blouse, senior vice president of translational research, provided preclinical results of CB 2679d-GT, the companys novel FIX gene therapy. CB 2679d-GT was designed to achieve clinically relevant FIX levels at a reduced viral load by combining engineered AAV capsids with Catalysts novel high potency FIX transgene.

The preclinical data from our constructs demonstrated a strong dose response and improved reduction in bleeding relative to the Padua variant, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. The enhanced FIX activity and reduced viral dose may offer advantages over current AAV-based gene therapies in clinical development.

Studies of CB 2679d-GT in hemophilia B mice have demonstrated a 4-fold reduction in blood loss and an 8-fold reduction in bleeding time when compared with the same dose of the Padua variant of FIX. Furthermore, when packaged in a proprietary chimeric AAV capsid, CB 2679d-GT demonstrated a clear dose response of high stable FIX levels across the three dose levels in hemophilia B mice.

A pilot non-human primate study compared the expression and tolerability of CB 2679d-GT in the novel chimeric capsid KP1 with the LK03 capsid. The study demonstrated that CB 2679d-GT was well tolerated with high FIX expression that stabilized to approximately 25% to 50% FIX above baseline levels at the 6-week interim data cutoff. The novel chimeric capsid had differentiated and superior response to anti-capsid neutralizing antibodies than that observed for the LK03 comparator during the screening of non-human primates for the study.

A copy of the presentation slides can be accessed on the Events and Presentations section of the Catalyst website.

About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. Our protease engineering platform includes development programs in hemophilia, a research program on subcutaneous (SQ) systemic complement inhibitors and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). One of our key competitive advantages is that the product candidates generated by our protease engineering platform have improved functionality and potency. These characteristics allow for improved dosing of our candidates including SQ systemic administration of recombinant coagulation factors and complement inhibitors, low-dose, high activity gene therapy constructs, and less frequently dosed intravitreal therapeutics. Our most advanced asset, SQ MarzAA has successfully completed Phase 2 development in prophylaxis, significantly reducing the annualized bleed rate (ABR) in individuals with Hemophilia A or B with inhibitors. Following regulatory guidance from the U.S. Food and Drug Administration and European Medicines Agency, we recently announced the design of a Phase 3 registration study that is planned for late 2020. Subcutaneous dalcinonacog alfa (DalcA) is being developed for the treatment of Hemophilia B and has demonstrated efficacy and safety in a Phase 2b clinical trial. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry AMD.

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the superiority of CB 2679d-GT over the Padua variant, enhanced FIX activity of CB 2679d-GT, which may reduce viral dose and maintain high FIX activity levels while potentially decreasing liver toxicity, the chimeric capsid, which may have lower neutralization by pre-existing AAV antibodies, as well as plans for a Phase 3 trial of MarzAA in late 2020 and the Companys collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 virus and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from animal trials or earlier human trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Companys products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalysts agreement, competition and other risks described in the Risk Factors section of the Companys quarterly report filed with the Securities and Exchange Commission on May 11, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:Ana KaporCatalyst Biosciences, Inc.investors@catbio.com

See the original post here:
Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020 -...

Recommendation and review posted by Bethany Smith

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read more:
Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall - Endpoints News

Recommendation and review posted by Bethany Smith

Gene Therapy Market Report Global analysis report is very helpful in understanding the Gene Therapy market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. The current market is evolving its presence and some of the major players in the study areGlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc..

The Gene Therapy Market research study will give the answer to questions about the present performance of the market and the competitive scope, opportunity, challenges, cost, and more. The market can be divided based on product types and its sub-type, key applications, and major regions. Then it discusses recent product innovations and provides a scenario of potential regional market shares. It aims to fulfill your targeted customers understanding, needs, and wants as well as to explain how effectively a company can meet its requirements.

Note: *The Download PDF brochure only consists of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.

Request A PDF Sample Copy Gene Therapy Market Report Click here: https://www.coherentmarketinsights.com/insight/request-pdf/1774

Highlights of the Global Gene Therapy report:

Overall data will help improve clients competitive study, economic decision-making ability, as well as business planning, and the scope of futuristic developments in the global Gene Therapy market. The complex data is explained in a well-structured manner by the experts and for which they used various analytical techniques and represent the data in the form of graphs, flowcharts, and diagrams.

Important Facts About Gene Therapy Market Report:

The Gene Therapy industry report features different approaches and procedures endorsed by the market key players to make vital business decisions.

The keyword market depicts some parameters such as production value, Gene Therapy marketing strategy analysis, Distributors/Traders, and effect factors are also mentioned in this Gene Therapy Market research report.

This research report reveals Gene Therapy market overview, product overview, market share, supply chain analysis, demand and supply ratio, and import/export details.

Key Topics Covered in this Gene Therapy Market Study:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Market EcosystemMarket CharacteristicsMarket Segmentation Analysis

Part 05: Market Sizing

Gene Therapy Market DefinitionMarket SizingMarket Size And Forecast

Part 06: Five Forces Analysis

Bargaining Power of BuyersBargaining Power of SuppliersThe threat of New EntrantsThreat of SubstitutesThreat of RivalryMarket Condition

Part 07: Customer Landscape Part 08: Regional Landscape

Geographical SegmentationRegional ComparisonAmericas Market Size And ForecastEMEA Market Size And ForecastAPAC Market Size And Forecast

Part 09: Decision Framework Part 10: Drivers And Challenges

Market DriversMarket Challenges

Part 11: Market Trends Part 12: Vendor Landscape

OverviewLandscape DisruptionVendors CoveredVendor ClassificationMarket Positioning Of Vendors

Have Any Query? Ask Our Industry Expert @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1774

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Read more from the original source:
Covid-19 Impact On Gene Therapy Market to Perceive Substantial Growth with Top Players like GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune...

Recommendation and review posted by Bethany Smith

Prophecy Market Insights Gene Therapy market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Gene Therapy market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Gene Therapy report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/39

The Gene Therapy research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Gene Therapy market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Gene Therapy market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Gene TherapyMarket Key Companies:

GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc.

Segmentation Overview:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Gene Therapy market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/39

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Gene Therapy market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Read this article:
Gene Therapy Market: Predictable To Witness Sustainable Evolution over 2020-2030 - Cole of Duty

Recommendation and review posted by Bethany Smith

A new research report released by MarketsandResearch.biz with the title Global Gene Therapy Market Growth (Status and Outlook) 2020-2025covers the overall analysis of the market, detailing information about key players, sales, future trends, research findings, and current and future opportunities during 2020 to 2025 forecast period. The report significantly identifies the qualitative influence of various market factors on market segments and geographies. The report defines, segments the global Gene Therapy market and encompasses market potential, influential trends, and issues facing the market. The report categorizes segments the market on the basis of product type, application, technology, and region.

Market Rundown:

To offer more clarity regarding the industry, the report takes a closer look at the current status of different factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries. In the end, the report makes some important proposals for a new project of Gene Therapy market before evaluating its possibility. The report includes factors like industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The study offers business owners, stakeholders, and field marketing personnel with a significant evaluation of other factors such as demand and supply status, import and export, distribution channel, consumption volume, and production capability.

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Gene Therapy market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/61287

The market report covers the following companies: Bluebird Bio, Sangamo, Dimension Therapeutics, Avalanche Bio, Spark Therapeutics, Advantagene, Celladon, Vical Inc.,

Market segment by product type, along with their consumption (sales), market share and growth rate includes: Ex vivo, In Vivo,

Market segment by application, along with their consumption (sales), market share and growth rate covers: Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other

Furthermore, thoughts and opinions from companies and individuals in the report who are unbiased and less emotionally attached to recent developments, products, or services are listed in the report. Industry experts conducting the study further estimate the potential of the global Gene Therapy industry. According to the analysts, this information is important for firms looking to launch an innovative service or product on the market.

Market Segmentation By Region:

Further, in the report, analysis of the regional market information is covered by separating major different regions as, Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries). It focuses on analyzing the geographical subdivisions of the global Gene Therapy market based on factors such as key regions, with production, consumption, revenue (million USD), and market share and growth rate of the market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/61287/global-gene-therapy-market-growth-status-and-outlook-2020-2025

The Study Aims Are:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

See the original post here:
Global Gene Therapy Market 2020 Trends, Business Opportunities, Future Demand and Forecast 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Global CRISPR Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

The global CRISPR market is estimated to expand at a CAGR of 23.95% over the forecasting period 2019-2028.

The increasing lifestyle-oriented diseases, the rising prevalence of genetic diseases and the growing application of drugs are the primary factors driving the growth of the CRISPR market. In addition, the increasing geriatric population and the rising incidence of genetic ailments are also likely to lead to an increase in demand for global CRISPR technology.

However, ethical issues associated with the technology and the changing regulatory environment is restraining the market. The market is also challenged by the availability of alternate technologies and the lack of awareness regarding CRISPR. But, the advancements in the gene-based therapy application and the increased demand for CRISPR will create market opportunities.

The global market report covers the countries from North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Asia-Pacific is likely to be the fastest-growing for the CRISPR market in the world. With the rapidly advancing technological developments and the wide range of applications of CRISPR technology in countries like India and China, regional growth is expected in the next few years. China has already started various gene-editing research work focusing on the CRISPR technology market.

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/so6ult

Continue reading here:
Global CRISPR Market (2019 to 2028) - Advancements in the Applications of Gene-Based Therapy Presents Opportunities - ResearchAndMarkets.com -...

Recommendation and review posted by Bethany Smith

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the ophthalmology therapeutics market and it is poised to grow by USD 10.42 billion during 2020-2024, progressing at a CAGR of almost 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increase in prevalence of eye diseases has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/report/ophthalmology-therapeutics-market-industry-analysis

Ophthalmology Therapeutics Market 2020-2024: Segmentation

Ophthalmology Therapeutics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40882

Ophthalmology Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The ophthalmology therapeutics market report covers the following areas:

This study identifies the development of novel drug delivery systems as one of the prime reasons driving the ophthalmology therapeutics market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Ophthalmology Therapeutics Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Assessment of COVID-19's Effect on Ophthalmology Therapeutics Market 2020-2024 | Increase in Prevalence of Eye Diseases to Augment Growth | Technavio...

Recommendation and review posted by Bethany Smith

-New Data Highlights the Flexibility of OncoSec's Therapeutic Platform to Enable Greater Anti-Tumor Activity with the Next-Generation TAVOPLUSIL-12 Plasmid

PENNINGTON, N.J. and SAN DIEGO, June 22, 2020 /PRNewswire/ --OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12 (IL-12) plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9). These product candidates, coupled with the new low-voltage electroporation gene delivery system, represent a promising approach for treating patients with a variety of solid tumors.The data were presented today during two late-breaking poster presentations at the American Association for Cancer (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.

"Multiple studies haveused intratumoral plasmid IL-12 (TAVO)to treat solid tumor indications with a demonstrable clinical benefit due to thiscytokine's ability to drive deep and durable immune responses," said Christopher Twitty, Ph.D., OncoSec's Chief Science Officer. "The new preclinical data exhibited in both AACR presentations highlights the evolution of OncoSec's IL-12-based platform. Incorporation of a chemokine gradient and a polyclonal T cell stimulator with the enhanced IL-12 backbone of TAVOPLUS holds significant potential in the treatment of solid tumors. We believe these data provide a strong rationale for filing an Investigational New Drug application and we are excited to advance TAVOPLUS into clinical development."

The following posters were presented during the session titled, "Late-Breaking Research: Immunology 2":

Title:"Intratumoral electroporation of plasmid-encoded IL-12 and membrane-bound anti-CD3 increases tumor immunogenicity and augments the function of T cell subsets"Poster Number:14Abstract Number:LB-390

Study Highlights:

Compared to IT-tavo-EP, TAVO+-CD3 enhances T cells engagement with tumor cells and augments T cell killing function in preclinical cancer models by:

Title:"Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of CXCL9 synergizes with IL-12 gene therapy (TAVO) to elicit robust anti-tumor immunity"Poster Number:20Abstract Number:LB-396

Study Highlights:

The full abstracts presented at the AACR Virtual Meeting II are available online at http://www.aacr.org and the posters are available on OncoSec's website at http://www.oncosec.com.

About OncoSec Medical IncorporatedOncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with the anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in two KEYNOTE clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 trial in metastatic triple negative breast cancer. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its novel Visceral Lesion Applicator designed to target deep internal lesions, such as liver, lung or pancreatic lesions. For more information, please visitwww.oncosec.com.

TAVOis a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking StatementsThis release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials, the allowance by FDA of the clinical use of CORVax12 and our next-generation APOLLO generator in this or any future clinical trials, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's websitewww.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Company Contact:Gem HopkinsHead of Corporate Communications858-210-7334[emailprotected]

SOURCE OncoSec Medical Incorporated

http://www.oncosec.com

View post:
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II -...

Recommendation and review posted by Bethany Smith

Pancreatic tumors employ multiple strategies for evading treatment, making them quick to spread and difficult to treat effectively. At this weeks virtual meeting of the American Association for Cancer Research (AACR), several research groups are presenting new therapeutic tactics aimed at interrupting survival pathways in pancreatic cancer.

A research team led by the University of Minnesota is investigating a combination of blocking both the immune checkpoint PD-L1 and CD40, a cell-surface molecule that also moderates the immune response to cancer. In mouse models of pancreatic cancer, either therapy alone prolonged survivalbut the tumors recurred in 100% of the animals. The researchers found tumor escape variants in key genes.

When the team tested a combination of PD-L1 and CD40 blockade, 60% of the mice were cured, the researchers reported at AACR.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

They went on study gene expression in the tumors of the animals that received the combination treatment. They discovered an accumulation of tumor-specific T cells capable of eradicating pancreatic tumors. Whats more, the anti-PD-L1 and anti-CD40 combination prompted an accumulation of memory T cells in the pancreascells that could be critical for preventing recurrences. They plan to discuss the findings in detail on Wednesday.

CD40 is a popular target for researchers investigating cancer combination treatments. Roche, for example, is testing its CD40 drug, selicrelumab, in combination with its PD-L1 blocker Tecentriq in solid tumors.

RELATED: An immuno-oncology triplet from Roche shows promise in mouse models of several tumors

Tyme Technologies is pursuing a different strategy for preventing tumor escapeone that hinges on cancer metabolism. Its drug, SM-88 (racemetyrosine), is designed to alter protein synthesis, increase oxidative stress and change other metabolic factors in ways that hamper the ability of the cancer cells to survive.

Tyme used cell lines and mouse models to characterize the anti-cancer effects of SM-88, which is currently being tested in a pivotal clinical trial in metastatic pancreatic cancer.

At the AACR virtual conference, Tyme reported that SM-88 disrupted autophagy in two types of pancreatic cancer cells. Autophagy is the process by which cells recycle waste products so they can survive.

In mouse models of pancreatic cancer, the drug reduced levels of regulatory T lymphocytes and M2 macrophagescells that suppress the immune response to cancerTyme showed in a poster presentation (PDF).

Tyme has started a phase 2/3 trial that will combine SM-88 with three other treatments in patients with metastatic pancreatic cancer who have failed two previous lines of therapy.

Excerpt from:
AACR: Attacking pancreatic cancer by thwarting its survival strategies - FierceBiotech

Recommendation and review posted by Bethany Smith

Prophecy Market Insights Personalized Gene Therapy Treatment market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Personalized Gene Therapy Treatment market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Personalized Gene Therapy Treatment report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/61

The Personalized Gene Therapy Treatment research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Personalized Gene Therapy Treatment market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Personalized Gene Therapy Treatment market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Personalized Gene Therapy TreatmentMarket Key Companies:

Amgen, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., SynerGene Therapeutics, Inc., Cold Genesys, Inc., Bellicum Pharmaceuticals, Inc., Takara Bio, Inc.,Ziopharm Oncology, Inc., , Sevion Therapeutics, Inc., OncoSec Medical, Inc., and Burzynski Clinic.

Segmentation Overview:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Personalized Gene Therapy Treatment market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/61

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Personalized Gene Therapy Treatment market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Read the original here:
2020 Prediction for Personalized Gene Therapy Treatment market: Key Players and Driving Factors Analysis - Cole of Duty

Recommendation and review posted by Bethany Smith

TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying established metastatic cervical and breast cancer (p=0.001; p=0.002). Data are presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held June 2224, 2020.

"Identifying a tumor-specific target is a key step for developing precise and safe immunotherapy for cancer, and MOSPD2 may be an ideal target. Our new data provide in-vitro and in-vivo proof-of-concept for the potential of VBL's novel MOSPD2 bi-specific antibody candidates for immuno-oncology mediated therapy for solid tumors," said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.

VBL's research has identified MOSPD2 as a protein involved in cell motility, whose expression is highly elevated in various solid tumors. The proprietary bi-specific antibody candidates developed by VBL have two separate arms one arm binds to MOSPD2 on tumor cells and the second recruits host T-cells that attack the tumor. The data presented today demonstrate that the company's bi-specific antibody candidates: 1) mediated killing of tumor cells by CD8 T-cells in a dose-dependent manner; 2) induced T-cell activation in-vivo; and 3) extended survival of tumor-bearing animals. The results highlight the potential of MOSPD2-mediated immuno-oncology therapy for the treatment of various solid tumors.

For VBL's poster presentations at AACR kindly see the following links:LB-poster and Poster2

About VBL's VB-600 PlatformVBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 investigational monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored all comers phase 1 trial as well as in three VBL-sponsored tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including MOSPD2, including their clinical development, therapeutic potential and clinical results and the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

Excerpt from:
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of...

Recommendation and review posted by Bethany Smith

Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing

Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today presentations of preclinical findings on the gene editing of natural killer (NK) cells and therapeutic combinations of engineered NK cells and T cells. The findings were presented in two posters at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II.

As we advance our two co-lead programs for engineered NK cells targeting NKG2D ligands and CD19, Nkarta continues to pioneer novel development approaches that leverage our platform capabilities in NK cell expansion, targeting, manufacturing and cryopreservation, said Paul J. Hastings, President and Chief Executive Officer of Nkarta. The findings presented today highlight the exciting potential of gene editing to add additional punch to the tumor killing properties of engineered NK cells and address the inhibitory checkpoints of the tumor microenvironment. In addition, we are encouraged by the early observation of beneficial effects when CAR NK cells and CAR T cells are combined as a potential NK Plus T anti-cancer therapeutic.

The exciting data generated by our scientists support our optimism about gene editing and immune cell combinations further propelling our pipeline of NK cell therapies, said James Trager, Chief Scientific Officer of Nkarta. These laboratory advances shine a light on the mechanisms behind the anti-cancer immune response. Were looking forward to learning more from our planned clinical studies about the most relevant ways to optimize NK cell performance using these approaches.

The posters are available on the AACR Virtual 2020 Annual Meeting II website and the Presentations section of the Nkarta website.

Details of Posters

Title: CRISPR-Cas9-gRNA RNP mediated gene knockout of TGFbR2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGFb

Poster number: 891 / 20

Session: PO.IM02.01 Adoptive Cell Therapy 1

Presentation time: June 22, 2020, 9:00am 6:00pm ET

Summary: An optimized CRISPR/Cas9 gene editing system was used successfully in engineered CAR NK cells to disrupt TGFbR2 and CISH, genes related to the downregulation of cytokine signaling and immune cell activation. TGFbR2 knockout CAR NK cells were resistant to TGFb-mediated inhibition of tumor cell killing. CISH knockout CAR NK cells had improved proliferation, survival, cytokine production and tumor cell killing. The findings showed that gene editing can be combined with engineering to enhance NK cell function and resist the inhibitory action of the tumor microenvironment.

Title: A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation

Poster number: 4235 / 9

Session: PO.CL06.02 Adoptive Cell Therapy 4 / Combination Immunotherapies

Presentation time: June 22, 2020, 9:00am 6:00pm ET

Summary: A novel platform combining CAR-NK and CAR-T cells enhanced anti-tumor cytotoxicity and persistence, lowered the accumulation of cytokines associated with cytokine release syndrome, promoted NK cell expansion while reducing antigen dependent proliferation of T cells, and prevented tumor relapse in an animal model for at least four months.

About Nkarta

Nkarta, Inc. focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkartas mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients. Founded in 2015, the companys investors include Amgen Ventures, Deerfield Management, LSP, Logos Capital, NEA, Novo Holdings A/S, RA Capital Management, Samsara BioCapital and SR One. For more information, please visit the companys website atwww.nkartatx.com.

Contact:

Greg MannNkarta, Inc.gmann@nkartatx.com

Sylvia WheelerWheelhouse Communicationsswheeler@wheelhouselsa.com

Continued here:
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at...

Recommendation and review posted by Bethany Smith

Dublin, June 22, 2020 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Region Coverage:

Company Coverage:

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Key Topics Covered:

1. Executive Summary

2. Introduction2.1 Regenerative Medicine: An Overview2.2 Regeneration in Humans: An Overview2.3 Expansion in Peripheral Industries of Regenerative Medicine2.4 Approval System for Regenerative Medicine Products2.5 Regenerative Medicine Segmentation

3. Global Market Analysis3.1 Global Regenerative Medicine Market: An Analysis3.1.1 Global Regenerative Medicine Market by Value3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics)3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals)3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis3.2.1 Global Cell Therapy Regenerative Medicine Market by Value3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value3.2.3 Global Gene Therapy Regenerative Medicine Market by Value3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis3.3.1 Global Biologically Derived Material Market by Value3.3.2 Global Synthetic Material Market by Value3.3.3 Global Genetically Engineered Materials Market by Value3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis4.1 North America Regenerative Medicine Market: An Analysis4.2 Europe Regenerative Medicine Market: An Analysis4.3 Asia Pacific Regenerative Medicine Market: An Analysis4.4 ROW Regenerative Medicine Market: An Analysis

5. COVID-195.1 Impact of Covid-195.2 Response of Industry to Covid-195.3 Variation in Organic Traffic5.4 Regional Impact of COVID-19

6. Market Dynamics6.1 Growth Drivers6.1.1 Growth in Geriatric Population6.1.2 Rising Global Healthcare Expenditure6.1.3 Increasing Diabetic Population6.1.4 Escalating Number of Cancer Patients6.1.5 Rising Prevalence of Cardiovascular Disease6.1.6 Surging Obese Population6.2 Challenges6.2.1 Legal Obligation6.2.2 High Cost of Treatment6.3 Market Trends6.3.1 3D Bio-Printing6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape7.1 Global Regenerative Medicine Market Players: A Financial Comparison7.2 Global Regenerative Medicine Market Players' by Research & Development Expenditure

8. Company Profiles8.1 Bristol Myers Squibb (Celgene Corporation)8.1.1 Business Overview8.1.2 Financial Overview8.1.3 Business Strategy8.2 Medtronic Plc8.2.1 Business Overview8.2.2 Financial Overview8.2.3 Business Strategy8.3 Smith+Nephew (Osiris Therapeutics, Inc.)8.3.1 Business Overview8.3.2 Financial Overview8.3.3 Business Strategy8.4 Novartis AG8.4.1 Business Overview8.4.2 Financial Overview8.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/w15smu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original here:
Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities - GlobeNewswire

Recommendation and review posted by Bethany Smith

CMI presents an in-depth overview of the Global Viral Vectors and Plasmid DNA Manufacturing Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics..

This study focuses on the Global Viral Vectors and Plasmid DNA Manufacturing market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Viral Vectors and Plasmid DNA Manufacturing growth in Key regions. In order to provide valuable insight by each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request A Sample Copy Viral Vectors and Plasmid DNA Manufacturing Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/962

The Global Viral Vectors and Plasmid DNA Manufacturing is segmented by:

By Product Type: Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report includes Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Enquire here get customization & check discount, please click: https://www.coherentmarketinsights.com/insight/request-discount/962

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Viral Vectors and Plasmid DNA Manufacturing Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Analysis of M&As, Partnership & JVs in Global Viral Vectors and Plasmid DNA Manufacturing Industry in the United States & Other Emerging Geographies

Top 10 Global Viral Vectors and Plasmid DNA Manufacturing Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Viral Vectors and Plasmid DNA Manufacturing MARKET LANDSCAPE

Market EntropyMarket segmentation analysisMarket characteristics

PART 06: Global Viral Vectors and Plasmid DNA Manufacturing MARKET SIZING

Market definitionMarket size and forecastMarket sizing

PART 07: Global Viral Vectors and Plasmid DNA Manufacturing MARKET SEGMENTATION

SegmentationMarket opportunityComparison

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Excerpt from:
Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Growth Analysis by Segmentation, Industry Size, Global Opportunities and Regional...

Recommendation and review posted by Bethany Smith

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Go here to see the original:
What's this? A rival bidder heads back to the table with a better offer for Tetraphase. Antibiotics show faint signs of life - Endpoints News

Recommendation and review posted by Bethany Smith